Harold Alfond Center for Cancer Care

Summary

Harold Alfond Center for Cancer Care is a medical facility located in Augusta, Maine. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Harold Alfond Center for Cancer Care is involved with conducting 147 clinical trials across 219 conditions. There are 10 research doctors associated with this hospital, such as Sarah J. Sinclair, Leslie Bradford, MD, Peter Rubin, and Rachit Kumar.

Top PIs

Clinical Trials running at Harold Alfond Center for Cancer Care

Ovarian Cancer

Lung Cancer

Breast Cancer

Breast cancer

Colorectal Cancer

Uterine Cancer

Cancer

Prostate Cancer

Multiple Myeloma

Non-Small Cell Lung Cancer

Selumetinib + Olaparib

for Ovarian and Endometrial Cancer

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.

Recruiting

1 award

Phase 2

Neratinib or Neratinib + Palbociclib

for Cancer

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.

Recruiting

1 award

Phase 2

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria